Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


22.10.2018

1 AJR Am J Roentgenol
2 BJU Int
1 BMC Cancer
1 Br J Cancer
1 Cancer Res
3 Clin Cancer Res
6 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
2 J Natl Cancer Inst
3 J Urol
2 Lancet Oncol
1 Oncogene
2 Oncol Rep
1 PLoS One
2 Proc Natl Acad Sci U S A
1 Prostate
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. METSER U, Chan R, Veit-Haibach P, Ghai S, et al
    Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
    AJR Am J Roentgenol. 2018 Oct 17:W1-W5. doi: 10.2214/AJR.18.20495.
    PubMed     Text format     Abstract available


    BJU Int

  2. BANDINI M, Marchioni M, Pompe RS, Tian Z, et al
    First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.
    BJU Int. 2018;121:592-599.
    PubMed     Text format     Abstract available

  3. VARMA M, Cochlin D, Delahunt B, Kynaston H, et al
    TNM clinical staging of prostate cancer: Issues and solutions.
    BJU Int. 2018 Oct 13. doi: 10.1111/bju.14589.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. MUSSAWY H, Viezens L, Schroeder M, Hettenhausen S, et al
    The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo.
    BMC Cancer. 2018;18:979.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. PELLACANI D, Droop AP, Frame FM, Simms MS, et al
    Phenotype-independent DNA methylation changes in prostate cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0236.
    PubMed     Text format     Abstract available


    Cancer Res


  6. Retraction: Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo.
    Cancer Res. 2018;78:6028.
    PubMed     Text format    


    Clin Cancer Res

  7. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1807.
    PubMed     Text format     Abstract available

  8. GARRIDO MF, Martin NJ, Bertrand M, Gaudin C, et al
    Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-0704.
    PubMed     Text format     Abstract available

  9. VAISHAMPAYAN U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, et al
    Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1473.
    PubMed     Text format     Abstract available


    Eur Urol

  10. HAJDINJAK T, Pelzer AE
    Re: What Are We Missing? False-negative Cancers at Multiparametric MR Imaging of the Prostate.
    Eur Urol. 2018;73:637.
    PubMed     Text format    

  11. KAMRAN SC, Seisen T, Markt SC, Preston MA, et al
    Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cance
    Eur Urol. 2018;73:e96-e97.
    PubMed     Text format    

  12. AUFFENBERG GB, Ghani KR, Ramani S, Usoro E, et al
    askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.
    Eur Urol. 2018 Oct 11. pii: S0302-2838(18)30740.
    PubMed     Text format     Abstract available

  13. PENNEY KL, Loda M, Stampfer MJ
    Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
    Eur Urol. 2018 Oct 12. pii: S0302-2838(18)30744.
    PubMed     Text format    

  14. VICKERS AJ, Lilja H, Assel M
    Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-u
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30743.
    PubMed     Text format    

  15. KASIVISVANATHAN V, Ambrosi A, Giganti F, Chau E, et al
    A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI.
    Eur Urol. 2018 Oct 13. pii: S0302-2838(18)30721.
    PubMed     Text format    


    Int J Cancer

  16. BEYNON R, Richmond RC, Santos Ferreira DL, Ness AR, et al
    Investigating the effects of lycopene and green tea on the metabolome of men at risk of prostate cancer: The ProDiet randomised controlled trial.
    Int J Cancer. 2018 Oct 16. doi: 10.1002/ijc.31929.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. CARLES J, Gallardo E, Domenech M, Font A, et al
    Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.
    Int J Radiat Oncol Biol Phys. 2018 Oct 12. pii: S0360-3016(18)33856.
    PubMed     Text format     Abstract available


    J Cell Physiol

  18. ZHU L, Zhu Q, Wen H, Huang X, et al
    Mutations in GAS5 affect the transformation from benign prostate proliferation to aggressive prostate cancer by affecting the transcription efficiency of GAS5.
    J Cell Physiol. 2018 Oct 14. doi: 10.1002/jcp.27561.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  19. MADAN RA, Gulley JL
    Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.
    J Natl Cancer Inst. 2018 Oct 13. pii: 5129110. doi: 10.1093.
    PubMed     Text format    

  20. ZHAO SG, Lehrer J, Chang SL, Das R, et al
    The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
    J Natl Cancer Inst. 2018 Oct 13. pii: 5129111. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Urol

  21. ETHERIDGE T, Liou JI, Downs TM, Abel EJ, et al
    The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  22. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Urol. 2018 Oct 9. pii: S0022-5347(18)43963-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available

  23. WALTON E, Yaguchi G, Keeley J, Deebajah M, et al
    Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    J Urol. 2018 Oct 11. pii: S0022-5347(18)43980-8. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    Lancet Oncol

  24. ROACH M, Moughan J, Lawton CAF, Dicker AP, et al
    Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
    Lancet Oncol. 2018 Oct 10. pii: S1470-2045(18)30528.
    PubMed     Text format     Abstract available

  25. DELOUYA G, Taussky D
    Pelvic radiotherapy in prostate cancer: an unresolved question.
    Lancet Oncol. 2018 Oct 10. pii: S1470-2045(18)30588.
    PubMed     Text format    


    Oncogene

  26. STELLOO S, Nevedomskaya E, Kim Y, Hoekman L, et al
    Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Oncogene. 2018;37:313-322.
    PubMed     Text format     Abstract available


    Oncol Rep

  27. MITRAN B, Andersson KG, Lindstrom E, Garousi J, et al
    Affibodymediated imaging of EGFR expression in prostate cancer using radiocobaltlabeled DOTAZEGFR:2377.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6792.
    PubMed     Text format     Abstract available

  28. NASSER MI, Han T, Adlat S, Tian Y, et al
    Inhibitory effects of Schisandrin B on human prostate cancer cells.
    Oncol Rep. 2018 Oct 15. doi: 10.3892/or.2018.6791.
    PubMed     Text format     Abstract available


    PLoS One

  29. LEIGHTON X, Bera A, Eidelman O, Bubendorf L, et al
    Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
    PLoS One. 2018;13:e0205837.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  30. FENG S, Cheng X, Zhang L, Lu X, et al
    Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
    Proc Natl Acad Sci U S A. 2018;115:10094-10099.
    PubMed     Text format     Abstract available

  31. ARORA H, Panara K, Kuchakulla M, Kulandavelu S, et al
    Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.
    Proc Natl Acad Sci U S A. 2018 Oct 15. pii: 1812704115.
    PubMed     Text format     Abstract available


    Prostate

  32. SEKINO Y, Oue N, Mukai S, Shigematsu Y, et al
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2018 Oct 16. doi: 10.1002/pros.23728.
    PubMed     Text format     Abstract available


    Urol Int

  33. MIYOSHI Y, Ohtaka M, Kawahara T, Ohtake S, et al
    Prediction of Time to Castration-Resistant Prostate Cancer Using Low-Molecular-Weight Protein Tyrosine Phosphatase Expression for Men with Metastatic Hormone-Naive Prostate Cancer.
    Urol Int. 2018 Oct 16:1-6. doi: 10.1159/000493324.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: